Treatment of mild headache in disabled migraine sufferers

Results of the spectrum study

R. K. Cady, Richard B. Lipton, Charles B. Hall, W. F. Stewart, S. O'Quinn, D. Gutterman

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

Original languageEnglish (US)
Pages (from-to)792-797
Number of pages6
JournalHeadache
Volume40
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Migraine Disorders
Headache
Pain
Sumatriptan
Placebos
Therapeutics
Recurrence
Drug-Related Side Effects and Adverse Reactions
Tablets
Safety
Pain-Free

Keywords

  • Disability
  • Migraine
  • Mild
  • Spectrum
  • Sumatriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Treatment of mild headache in disabled migraine sufferers : Results of the spectrum study. / Cady, R. K.; Lipton, Richard B.; Hall, Charles B.; Stewart, W. F.; O'Quinn, S.; Gutterman, D.

In: Headache, Vol. 40, No. 10, 2000, p. 792-797.

Research output: Contribution to journalArticle

Cady, R. K. ; Lipton, Richard B. ; Hall, Charles B. ; Stewart, W. F. ; O'Quinn, S. ; Gutterman, D. / Treatment of mild headache in disabled migraine sufferers : Results of the spectrum study. In: Headache. 2000 ; Vol. 40, No. 10. pp. 792-797.
@article{e8001683f9fa4023bd8ac00b06f7d377,
title = "Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study",
abstract = "Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78{\%} versus 0{\%}, P=.02), but not 2 hours postdose (52{\%} versus 0{\%}, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85{\%} versus 17{\%}) and 2 hours (50{\%} versus 0{\%}) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13{\%} versus 18{\%}). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.",
keywords = "Disability, Migraine, Mild, Spectrum, Sumatriptan",
author = "Cady, {R. K.} and Lipton, {Richard B.} and Hall, {Charles B.} and Stewart, {W. F.} and S. O'Quinn and D. Gutterman",
year = "2000",
doi = "10.1046/j.1526-4610.2000.00144.x",
language = "English (US)",
volume = "40",
pages = "792--797",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Treatment of mild headache in disabled migraine sufferers

T2 - Results of the spectrum study

AU - Cady, R. K.

AU - Lipton, Richard B.

AU - Hall, Charles B.

AU - Stewart, W. F.

AU - O'Quinn, S.

AU - Gutterman, D.

PY - 2000

Y1 - 2000

N2 - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

AB - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

KW - Disability

KW - Migraine

KW - Mild

KW - Spectrum

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0034527433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034527433&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4610.2000.00144.x

DO - 10.1046/j.1526-4610.2000.00144.x

M3 - Article

VL - 40

SP - 792

EP - 797

JO - Headache

JF - Headache

SN - 0017-8748

IS - 10

ER -